Evaluation of circulating small extracellular vesicle-derived miRNAs as diagnostic biomarkers for differentiating between different pathological types of early lung cancer

Jiang, Yuqian; Wei, Shan-na; Geng, Ning; Qin, Wen‐Wen; He, Xin; Wang, Xiu-huan; Qi, Yao-pu; Song, Shan; Wang, Ping

doi:10.1038/s41598-022-22194-0

Cited by 15 publications

(8 citation statements)

References 60 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Sozzi et al., reported that a combination of both plasma miRNA signature and LDCT resulted in the reduction of LDCT false-positive rate ( 16 ), highlighting the utility of miRNA in informing lung cancer diagnoses. Despite investigation describing miRNAs deregulation in lung cancers ( 17 ), few studies have identified a panel of miRNAs distinguishing SCLC from NSCLC ( 12 , 18 ). NSCLC represents the majority of lung cancer cases while SCLC remains a less common subtype of tumor that is often not considered in biomarker studies.…”

Section: Discussionmentioning

confidence: 99%

A plasma miRNA-based classifier for small cell lung cancer diagnosis

Saviana,

Romano,

McElroy

et al. 2023

Front. Oncol.

View full text Add to dashboard Cite

IntroductionSmall cell lung cancer (SCLC) is characterized by poor prognosis and challenging diagnosis. Screening in high-risk smokers results in a reduction in lung cancer mortality, however, screening efforts are primarily focused on non-small cell lung cancer (NSCLC). SCLC diagnosis and surveillance remain significant challenges. The aberrant expression of circulating microRNAs (miRNAs/miRs) is reported in many tumors and can provide insights into the pathogenesis of tumor development and progression. Here, we conducted a comprehensive assessment of circulating miRNAs in SCLC with a goal of developing a miRNA-based classifier to assist in SCLC diagnoses.MethodsWe profiled deregulated circulating cell-free miRNAs in the plasma of SCLC patients. We tested selected miRNAs on a training cohort and created a classifier by integrating miRNA expression and patients’ clinical data. Finally, we applied the classifier on a validation dataset.ResultsWe determined that miR-375-3p can discriminate between SCLC and NSCLC patients, and between SCLC and Squamous Cell Carcinoma patients. Moreover, we found that a model comprising miR-375-3p, miR-320b, and miR-144-3p can be integrated with race and age to distinguish metastatic SCLC from a control group.DiscussionThis study proposes a miRNA-based biomarker classifier for SCLC that considers clinical demographics with specific cut offs to inform SCLC diagnosis.

show abstract

Section: Discussionmentioning

confidence: 99%

A plasma miRNA-based classifier for small cell lung cancer diagnosis

Saviana,

Romano,

McElroy

et al. 2023

Front. Oncol.

View full text Add to dashboard Cite

show abstract

“…Four specific miRNAs (Let-7b-3p, miR-150-3p, miR-145-3p, and miR-139-3p) were identified in the plasma of cancer patients, suggesting their potential role as biomarkers for CRC diagnosis [ 21 ]. In early lung cancer detection, miRNA profiles were analyzed using plasma-derived sEVs from healthy controls, patients with small cell lung cancer (SCLC), and patients with non-small cell lung cancer (NSCLC) [ 22 ]. miRNA-483-3p showed potential as an early diagnostic biomarker for SCLC, while miRNA-152-3p and miRNA-1277-5p were identified as early diagnostic biomarkers for NSCLC [ 22 ].…”

Section: Sevs As Cancer Biomarkersmentioning

confidence: 99%

“…In early lung cancer detection, miRNA profiles were analyzed using plasma-derived sEVs from healthy controls, patients with small cell lung cancer (SCLC), and patients with non-small cell lung cancer (NSCLC) [ 22 ]. miRNA-483-3p showed potential as an early diagnostic biomarker for SCLC, while miRNA-152-3p and miRNA-1277-5p were identified as early diagnostic biomarkers for NSCLC [ 22 ]. Nasopharyngeal carcinoma (NPC) is usually diagnosed at a late stage and consequently shows a poor prognosis after treatment [ 23 ].…”

Section: Sevs As Cancer Biomarkersmentioning

confidence: 99%

Emerging Roles of Using Small Extracellular Vesicles as an Anti-Cancer Drug

Joo,

Suh,

et al. 2023

IJMS

View full text Add to dashboard Cite

Small extracellular vesicles (sEVs) are emerging as a novel therapeutic strategy for cancer therapy. Tumor-cell-derived sEVs contain biomolecules that can be utilized for cancer diagnosis. sEVs can directly exert tumor-killing effects or modulate the tumor microenvironment, leading to anti-cancer effects. In this review, the application of sEVs as a diagnostic tool, drug delivery system, and active pharmaceutical ingredient for cancer therapy will be highlighted. The therapeutic efficacies of sEVs will be compared to conventional immune checkpoint inhibitors. Additionally, this review will provide strategies for sEV engineering to enhance the therapeutic efficacies of sEVs. As a bench-to-bedside application, we will discuss approaches to encourage good-manufacturing-practice-compliant industrial-scale manufacturing and purification of sEVs.

show abstract

“…Furthermore, multiple studies on EV-based diagnosis of cancer have suggested that EV transcriptomic and proteomic biomarkers can increase the likelihood of early and sensitive detections of cancer. For example, plasma EV-derived miRNA-483-3 could be used as a potential biomarker for the diagnosis of early-stage small cell lung cancer, and miRNA-152-3p and miRNA-1277-5p could be used for the diagnosis of early-stage non-small cell lung cancer [ 18 ]. Glypican 1 (GCP1) and macrophage migration inhibitory factor (MIF) were identified as potential exosome-associated biomarkers for early diagnosis of pancreatic cancer [ 19 , 20 ].…”

Section: Introductionmentioning

confidence: 99%

Glycoproteomic Analysis of Urinary Extracellular Vesicles for Biomarkers of Hepatocellular Carcinoma

Jia

Wang

et al. 2023

Molecules

View full text Add to dashboard Cite

Hepatocellular carcinoma (HCC) accounts for the most common form of primary liver cancer cases and constitutes a major health problem worldwide. The diagnosis of HCC is still challenging due to the low sensitivity and specificity of the serum α-fetoprotein (AFP) diagnostic method. Extracellular vesicles (EVs) are heterogeneous populations of phospholipid bilayer-enclosed vesicles that can be found in many biological fluids, and have great potential as circulating biomarkers for biomarker discovery and disease diagnosis. Protein glycosylation plays crucial roles in many biological processes and aberrant glycosylation is a hallmark of cancer. Herein, we performed a comprehensive glycoproteomic profiling of urinary EVs at the intact N-glycopeptide level to screen potential biomarkers for the diagnosis of HCC. With the control of the spectrum-level false discovery rate ≤1%, 756 intact N-glycopeptides with 154 N-glycosites, 158 peptide backbones, and 107 N-glycoproteins were identified. Out of 756 intact N-glycopeptides, 344 differentially expressed intact N-glycopeptides (DEGPs) were identified, corresponding to 308 upregulated and 36 downregulated N-glycopeptides, respectively. Compared to normal control (NC), the glycoproteins LG3BP, PIGR and KNG1 are upregulated in HCC-derived EVs, while ASPP2 is downregulated. The findings demonstrated that specific site-specific glycoforms in these glycoproteins from urinary EVs could be potential and efficient non-invasive candidate biomarkers for HCC diagnosis.

show abstract

Evaluation of circulating small extracellular vesicle-derived miRNAs as diagnostic biomarkers for differentiating between different pathological types of early lung cancer

Cited by 15 publications

References 60 publications

A plasma miRNA-based classifier for small cell lung cancer diagnosis

A plasma miRNA-based classifier for small cell lung cancer diagnosis

Emerging Roles of Using Small Extracellular Vesicles as an Anti-Cancer Drug

Glycoproteomic Analysis of Urinary Extracellular Vesicles for Biomarkers of Hepatocellular Carcinoma

Contact Info

Product

Resources

About